Table of Contents Table of Contents
Previous Page  872 1030 Next Page
Information
Show Menu
Previous Page 872 1030 Next Page
Page Background

Importantly, the study reported no difference in EORTC

QLQ-C30–assessed global QoL, up to 5 yr of follow-up.

However, Expanded Prostate Cancer Index Composite

(EPIC) urinary summary scores were worse in men treated

with RP compared with active monitoring or EBRT (88.7 vs

89.0 vs 91.4, respectively) as were urinary incontinence

(80.9 vs 85.8 vs 89.4, respectively) and sexual summary,

function, and bother scores (32.3 vs 40.6 vs 41.3 for sexual

summary, 23.7 vs 32.5 vs 32.7 for sexual function, and

51.4 vs 57.9 vs 60.1 for sexual bother, respectively) at 6 yr of

follow-up. For men receiving EBRT, EPIC bowel scores

deteriorated initially, and although they improved after the

1st year, they were still poorer compared with active

monitoring and RP at 6 yr post-treatment in all domains:

summary (91.2 vs 93.2 vs 93.0, respectively), function

(90.8 vs 92.3 vs 92.3, respectively), and bother (91.7 vs

94.2 vs 93.7, respectively).

3.4.1.2. RP versus BT.

For the comparison of RP versus BT, data

were obtained from two RCTs. The Surgical Prostatectomy

[(Fig._1)TD$FIG]

Abstracts and titles screened

(

n

=12 420)

Articles identified for full-

text screening (

n

= 130)

Records excluded

(

n

= 12 290)

Articles full-text

screened (

n

= 130)

Studies excluded (

n

=110)

2 theses/reviews

1 article reporting study

design

12 using a nonvalidated

patient-reported

outcome questionnaire

5 studies not reporting

all domains of cancer-

specific QoL

questionnaire

9 retrospective studies

17 no outcomes by

intervention

34 include patients with

nonclinically localised

PCa

1 not comparative

1 <10 participants per

arm

24 no eligible

comparator

2 follow-up <12 mo

2 authors contacted but

did not respond

regarding raw data

18 studies included

(

n

= 20 reports)

Abstracts and titles identified

through database searching

(

n

= 12 420)

Fig. 1 – PRISMA flow diagram. QoL = quality of life; PCa = prostate cancer; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-

analyses.

E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 6 9 – 8 8 5

872